The nation of Zimbabwe has declined a major American healthcare agreement worth $367m (272 million pounds) over five years over the United States' request for confidential information.
This rejection came to light following a official document dated December was leaked, indicating that President Emmerson Mnangagwa believed the arrangement was "unbalanced".
An official spokesperson later explained that the US was requesting health data for research and profit but was not willing to guarantee the resulting advantages from any future vaccines.
"We are forced to start the difficult and regrettable process of ending our support in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont publicly.
Her embassy noted the US had provided more than $1.9bn for health programmes to Zimbabwe during the past twenty years.
A medical body in Zimbabwe has urged more talks to find a deal suitable to both sides so the country's vital HIV treatment initiative can proceed.
Wider Context
This development comes after a similar case in neighbouring Kenya, where a high court halted a similar deal with the US following concerns were raised about the security of Kenyans' medical information.
After returning to the presidency recently, US President Donald Trump has reduced overseas assistance and shut down the US Agency for International Development (USAID).
The agency had overseen aid for the US government, but Trump claimed its spending was "inefficient" and his government was seeking government-to-government deals to boost transparency and accountability.
Based on statements, 16 nations in Africa have so far signed these new health pacts, constituting over $18.3bn of fresh investment.
Details of the Declined Agreement
The funds for Zimbabwe would have funded "tackling HIV/Aids, tuberculosis, malaria, maternal and child health, and disease outbreak preparedness.
"It is our view this collaboration would have delivered extraordinary benefits for the people of Zimbabwe, particularly the 1.2 million currently receiving HIV treatment via US-supported initiatives," the Ambassador said.
However, official spokesman Nick Mangwana said the arrangement was "unequal".
"The proposal required Zimbabwe to provide its genetic material and health information for a long time, without any corresponding assurance of access to any medical innovations – like vaccines, diagnostics, or treatments – that could be developed from that provided information," he stated.
"Effectively, our country would supply the raw materials for scientific discovery with no assurance that the end products would be available to our people should a future pandemic arise."
National Interest and Global Health
He also pointed out that the American exit from the global health body and its push of one-on-one deals were disrupting structures already set up through the international health agency.
The spokesperson gave as an example its Pathogen Access and Benefit Sharing scheme created to manage future pandemics.
"This system is designed to guarantee that when a country contributes its data, the resulting advantages – including medicines and cures – are distributed fairly, not commercialised solely by those with the capability to develop them."
These objections regarding the US deal "are not meant as anti-American sentiment," he added.
"We encourage continued discussions with our American counterparts on how future co-operation could be arranged in a manner that respects the independence and dignity of both nations."
Medical Community Reaction
A leading public health body stated it understood the official position, but suggested that talks must proceed considering a large portion of the country's Aids initiatives depended on external financing.
"If specific concerns exist, such as those relating to information security or agreement terms, these can frequently be resolved via technical clarification and negotiated safeguards," the group said.
The situation highlights the continuing debate between accepting much-needed foreign assistance and safeguarding national sovereignty in an ever more data-driven world.